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Abstract
An inverse relationship appears to exist between cigarette smoking and the risk of Parkinson’s and Alzheimer’s diseases.
Since both diseases are characterized by enhanced oxidative stress, we investigated the antioxidant potential of nicotine, a
primary component of cigarette smoke. Initial chromatographic studies suggest that nicotine can affect the formation of the
neurotoxin 6-hydroxydopamine resulting from the addition of dopamine to Fenton’s reagent (i.e., Fe2 and H2O2). Thus,
under certain circumstances, nicotine can strongly affect the course of the Fenton reaction. In in vivo studies, adult male rats
being treated with nicotine showed greater memory retention than controls in a water maze task. However, neurochemical
analysis of neocortex, hippocampus, and neostriatum from these same animals revealed that nicotine treatment had no effect
on the formation of reactive oxygen species or on lipid peroxidation for any brain region studied. In an in vitro study,
addition of various concentrations of nicotine to rat neocortical homogenates had no effect on lipid peroxidation compared
to saline controls. The results of these studies suggest that the beneficial/protective effects of nicotine in both Parkinson’s
disease and Alzheimer’s disease may be, at least partly, due to antioxidant mechanisms. ß 1999 Elsevier Science B.V. All
rights reserved.
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1. Introduction
Numerous epidemiological studies have demon-
strated an inverse relationship between cigarette
smoking and the risk of developing idiopathic Par-
kinson’s disease (PD) [1^4]. One of the compounds in
cigarette smoke thought to be responsible for this
e¡ect might be nicotine. Studies have demonstrated
that not only cigarette smoke, but also nicotine gum
and nicotine patches, can decrease the tremors and
bradykinesia of PD [5,6]. In addition to PD, cigarette
smoking/nicotine appears to have an inverse relation-
ship with Alzheimer’s disease (AD) [7,8]. Consistent
with such a relationship, nicotine administration to
AD patients enhances their attention and informa-
tion processing [9^12]; in addition, it has been found
that nicotine treatment improves the cognitive func-
tion of both young and aged rats [13^15].
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There is increasing evidence for the involvement
of free radicals and iron (Fe)-induced oxidative
stress in the pathogenesis of Parkinson’s and Alz-
heimer’s diseases [16]. In PD brains, a speci¢c in-
crease in Fe levels occurs within the substantia nigra.
This could be a cause of the degeneration of
nigrostriatal dopaminergic (NS-DA) neurons that is
such a characteristic feature of PD. Most NS-DA
neurons contain neuromelanin deposits [17], which
bind higher amounts of Fe in PD [18] and increase
the vulnerability of NS-DA neurons to degeneration
in PD [17]. Given this evidence for the involvement
of Fe in PD, we have recently published a scheme
of reactions which could lead to an initiation and
continuation of PD pathogenesis [19]. The basic prin-
ciple is the fact that neurotoxic 6-hydroxydopamine
(6-OHDA) is formed from the oxidation of DA in
the presence of free (solvated) Fe(II) ions and H2O2
(i.e., Fenton’s reagent). In normal brains, almost all
Fe should be stored or bound in ‘storage com-
pounds’ like the protein ferritin, so that it should
be Fenton-inactive. However, it has been shown
that 6-OHDA is able to free Fe(II) from storage in
ferritin [20], thus facilitating the Fenton reaction
which in turn leads to further production of
6-OHDA. In NS-DA neurons, we propose that this
cycle is continuous, forming strongly oxidizing radi-
cals which destroy cellular components such as the
cell membrane.
If nicotine in cigarette smoke has a preventative
e¡ect towards PD, there are several possible mecha-
nisms involving the above reactions that could pro-
tect NS-DA neurons. One very plausible mechanism
of nicotine action in PD involves the known ability
of nicotine to form complexes with Fe(II), probably
via the pyridine nitrogen
1
However, no detailed structural investigations have
been done and coordination might also occur via the
pyrrolidine nitrogen. Consistent with the ability of
nicotine to bind Fe2 are studies reporting that:
(1) nicotine binds directly to the iron ions of throm-
boxane synthase, thus inhibiting that enzyme [23],
and (2) nicotine reduces transferrin-mediated Fe up-
take by reticulocytes and placental cells [24,25].
Based on the above ¢ndings, we hypothesized that
nicotine may be protective against PD through com-
plex formation with Fe(II), thus yielding Fenton-in-
active Fe(II) and less oxidative stress.
In the present study, we ¢rst investigated the ‘anti-
oxidant’ potential of nicotine as an inhibitor of the
Fenton reaction. In follow-up in vivo and in vitro
animal studies, we then sought to determine whether
nicotine’s mechanism of cognitive enhancement in
rats is associated with measurable antioxidant ac-
tions in several brain areas, as indexed by reactive
oxygen species (ROS) and thiobarbituric acid reac-
tive product (TBAR) formation.
2. Materials and methods
2.1. Chromatographic study
2.1.1. Chromatography
All experiments were performed using an HP
1090M LC with a UV/VIS detector connected to
an HP 79995A workstation (HP 9000 Computer,
Series 300). Samples were introduced using a 25 Wl
injection loop. Separations were carried out using a
250U4.6 mm ID ODS Hypersil 5W column, operated
at a £ow rate of 1.2 ml/min and at a temperature of
40‡C. The mobile phase consisted of methanol-aque-
ous acetic acid bu¡er (1:1, v/v). The bu¡er was pre-
pared by adding 240 mg sodium acetate crystals (p.a.
grade) to 1000 ml of water (HPLC grade) and then
adjusting the pH to 3.55 ( þ 0.02) with glacial acetic
acid (100%). Peak identi¢cations were performed by
admixture with authentic standards.
2.1.2. Chemicals
Dopamine (DA), 6-OHDA, and 5-OHDA were
obtained as the hydrochlorides from Sigma and
used without further puri¢cation. Nicotine (from Al-
drich) was puri¢ed via the dihydroiodide according
to Pictet and Genequand [26], followed by an extrac-
tion with ether after neutralization in aqueous solu-
tion.
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2.1.3. Sample preparation
To phosphate-bu¡ered solutions of DA (pH 7.5),
iron(II) and hydrogen peroxide were added and the
resulting mixture was made acidic (pH 1.0) after
1 min to slow down the reaction. Then the samples
were analyzed by HPLC as described above.
2.2. In vivo animal study
Twenty 2 month old male Sprague-Dawley rats
were pretreated for 4 days with twice daily intraper-
itoneal (i.p.) injections of nicotine (0.8 mg/kg, as the
hydrogen tartrate salt ; n = 10) or vehicle (isotonic
saline; n = 10). On day 5 of treatment, all rats began
4 days of acquisitional training (days 5^8) in the
Morris water maze. Three hours prior to behavioral
testing, rats received their ¢rst of two daily injections
of nicotine or saline. For all 4 days of acquisition,
mean latency to reach a submerged platform in
quadrant II was determined from four daily trials,
with each trial initiated in a di¡erent quadrant. On
day 9 of treatment, animals were given a 60 s mem-
ory retention trial at 3 h after their ¢rst of two daily
treatments with nicotine or saline. For this probe
trial, the platform was removed and animals were
placed in the quadrant opposite to the former plat-
form quadrant. The percentage of time spent in each
of the four quadrants was recorded. A preference for
the former platform quadrant, as indicated by a
greater amount of time spent in that quadrant, sug-
gests superior memory retention. Acquisitional data
were analyzed using two-way ANOVA for repeated
measures and memory retention data were analyzed
with a one-way ANOVA and Student’s t-test. Post-
hoc analysis involved Fischer’s LSD tests. A P-value
less than 0.05 was considered signi¢cant.
On day 10, a ¢nal treatment with nicotine or saline
was given and animals were euthanized within sev-
eral hours thereafter. Following brain removal, the
neocortex, hippocampus, and neostriatum were dis-
sected out bilaterally and weighed. Samples were
then quick frozen and stored at 380‡C until neuro-
chemical analysis. Reactive oxygen species (ROS)
formation was determined in the right tissue samples
via 2P,7P-dichloro£uorescein (DCF) £uorescence. Tis-
sues from the left side were assayed for thiobarbituric
acid reactive product (TBAR) formation, an index of
lipid peroxidation.
The DCF £uorescence assay for ROS detects pri-
marily the levels of hydrogen peroxide, superoxide
radical, and hydroxyl radical. Right side tissue sam-
ples were prepared for DCF £uorescence according
to the basic methodology of LeBel et al. [27]. A
0.25% homogenate was prepared for each sample
using cold bu¡er (40 mM Tris, pH 7.4). Samples
were incubated at 37‡C with 1.25 mM of 2P,7P-di-
chlorodihydro£uorescein diacetate (H2DCFDA) in
methanol for 15 min at 37‡C. Formation of the £uo-
rescent probe DCF was measured using a £uorome-
ter with excitation and emission wavelengths set at
488 nm and 525 nm, respectively. Readings were
taken immediately after incubation (time 0) and at
30 min intervals for 1.5 h thereafter. DCF formation
is reported in WM/Wg protein. Results were analyzed
using Student’s t-test, with P6 0.05 being considered
signi¢cant.
Left side tissue samples were prepared for TBAR
formation analysis according to the basic methodol-
ogy of Socci et al. [28]. In brief, 5% tissue homoge-
nates were prepared in a solution of isotonic saline
and Desferol (0.029 mM ¢nal concentration in ho-
Fig. 1. Chromatogram of the optimized separation of the stand-
ard solution containing equal amounts of dopamine, 6-OHDA,
and 5-OHDA. The peaks labeled as 6-OHDA and 5-OHDA
are in actual fact their oxidation products resulting from
oxidation on the column during the separation (detection at
265 nm).
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mogenate). To these homogenates, 300 Wl of 25%
trichloroacetic acid, 150 Wl of 1% thiobarbituric
acid, and 10 Wl 5% butylated hydroxytoluene
(BHT) were added. (Desferol (an iron chelator) and
BHT were included in the homogenization solution
to eliminate TBAR formation resulting from tissue
iron released during homogenization and from
breakdown of lipid hydroperoxides, respectively ^
this allowed a true determination of TBAR forma-
tion in each tissue.) Tissue solutions were incubated
for 45 min at 90‡C and then centrifuged for 10 min
at 15 000Ug. The change in supernatant color was
read spectrophotometrically at 535 nm. TBAR for-
mation is reported in pmol/Wg protein. Results were
analyzed using Student’s t-test, with P6 0.05 consid-
ered signi¢cant.
2.3. In vitro animal study
Neocortical tissue from ¢ve male Sprague-Dawley
rats (5 months old) was dissected out and used to
assess in vitro TBAR formation in the presence of
nicotine or Desferol. Tissue preparation for the in
vitro experiment followed the same TBAR formation
procedure as above, except at the step where Desfer-
ol was added prior to homogenizing. Six aliquots
were taken from each 5% tissue homogenate and
either Desferol (4.76 mM ¢nal homogenate concen-
tration), nicotine (0.71, 1.43, 2.38, or 4.76 mM ¢nal
homogenate concentration), or saline was added.
Thus, at this step, the process of chelating freed tis-
sue Fe during homogenization depended on either
Desferol (traditional chelator), nicotine (possible che-
Fig. 2. Oxidation of 6-OHDA in the presence of Fe(II,III) ions (UV/VIS spectra).
BBADIS 61836 11-6-99
W. Linert et al. / Biochimica et Biophysica Acta 1454 (1999) 143^152146
lator), or saline (no chelator). This allowed testing of
varying concentrations of nicotine for ability to sup-
press TBAR formation. Results are expressed as per-
cent change from the Desferol-containing homoge-
nate, as this homogenate represents ‘basal’ TBAR
formation (i.e., presumably no tissue iron was avail-
able to induce TBAR formation during the assay).
Statistical analysis between saline and either Desferol
standard or nicotine concentrations was done with
Student’s t-test, while comparisons between nicotine
concentrations were done with a repeated measures




In Fig. 1, the optimized separation of the standard
solution containing DA, 6- and 5-OHDA is shown.
5-OHDA and the neurotoxin 6-OHDA are possible
oxidation products of the investigated oxidation re-
action of DA with H2O2 in the presence of iron(II)
[29^31]. The peaks labeled as 6-OHDA and
5-OHDA, respectively, are in actual fact their oxida-
tion products resulting from oxidation on the column
during the separation. As both 5-OHDA and
6-OHDA are oxidized in the presence of dioxygen
in very short times under the given conditions, via
their semiquinones, to relatively stable quinones
[19,31,32], the oxidation products detected by
HPLC refer, therefore, to their respective quinones.
As no other oxidation products are found within this
time scale, quanti¢cation is possible on the basis of
the peak areas. This was veri¢ed not only for
6-OHDA (see Fig. 2), but also for 5-OHDA by
measurements on a Perkin-Elmer Lambda 15 UV/
VIS spectrophotometer. We could observe a shift
of the absorption maximum, in the case of
6-OHDA from 291.5 nm to 265 nm and of
5-OHDA from 270 nm to 235 nm. Therefore, we
used di¡erent wavelengths for UV/VIS detection on
the HPLC; for DA 280 ( þ 2) nm, for 6-OHDA 265
( þ 2), for 5-OHDA 235 ( þ 2) nm, and as reference
375^425 nm.
The occurrence of strong peak tailing is typical for
separations of basic compounds in acidic medium on
a reversed phase column, as we used it [33], and
seems to have its origin in Fe traces remaining on
the column. However, they do not in£uence the argu-
ment given by the HPLC results. The acidic medium
is needed to keep the oxidation process as minimal as
possible.
Fig. 3 shows that 6-OHDA is produced during the
oxidation of dopamine with H2O2 in the presence of
iron(II). For peak identi¢cation of the p-quinone of
6-OHDA, a reference spectrum at the beginning of
the peak (identi¢ed as dopaminochrome) was sub-
tracted from that of the peak maximum. The amount
of 6-OHDA built in the solution is, as expected, de-
pendent on both the iron(II) and H2O2 concentration
(see Figs. 4 and 5). In a two step reaction, about 1%
of the original available amount of DA reacts to
form neurotoxic 6-OHDA. However, this absolute
amount is not conclusive because of the occurrence
of both the autoxidation and oxidation of DA due to
the presence of hydrogen peroxide, yielding the re-
spective semiquinones followed by quinone and mel-
anin formation [19]. OHc radicals (or equally ferryl
species), might well act as oxidizing or hydroxylizing
species (reaction 2). Relative peak heights (or areas)
between the 6-OHDA and the DA peaks may serve
as quantitative tools for comparison.
2
Without going into a detailed kinetic analysis, the
results can be interpreted as an approximately ¢rst
order dependence of 6-OHDA production on Fe(II)
and an approach of a steady state concentration of
6-OHDA with increasing H2O2 concentration, as-
suming that 6-OHDA is further oxidized by H2O2
to ¢nally form melanin (Figs. 4 and 5).
To determine whether nicotine’s ability to form
complexes with iron(II) is capable of making iron(II)
Fenton-inactive, the analogous analysis was made
with nicotine added to the reaction mixture. Fig. 6
shows the production of 6-OHDA by addition of a
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5-fold molar excess of nicotine to the reaction mix-
ture. The amounts of 6-OHDA formed appear to be
reduced by a factor of 2 when compared to the
amount formed without nicotine. Adding nicotine
to an analogous solution of iron(III), the amount
of 6-OHDA produced was again reduced. However,
an equal amount of 5-OHDA appears to be formed
(Fig. 7). The sum of the areas below the 6-OHDA
and the 5-OHDA peaks in the presence of Fe(III)
equals the area below the 6-OHDA peak found in
the presence of Fe(II).
3.2. In vivo animal study
In water maze acquisition (Fig. 8A), there was no
signi¢cant di¡erence between saline-treated and nic-
otine-treated rats in overall learning or in the rate of
learning (Ps 0.05). Both groups improved their ac-
quisition performance, as seen by a decrease in laten-
cies over the 4 day test period (P6 0.001). In the
follow-up memory retention trial, however, only the
nicotine-treated group showed signi¢cant memory re-
tention (Fig. 8B). This enhanced memory is indicated
by the greater amount of time spent by nicotine-
treated rats in the quadrant (Q2) formerly containing
Fig. 6. Formation of 6-OHDA in a mixture of 5 mmol/l DA,
1 mmol/l Fe(II), and 1 mmol/l H2O2 in the presence of 5 mmol/
l nicotine (detection at 265 nm).
Fig. 5. Variation of 6-OHDA production with H2O2 concentra-
tion in a reaction mixture with 5 mmol/l DA, 2.5 mmol/l
Fe(II). The ¢tted line refers to a steady state assumption.
Fig. 4. Variation of 6-OHDA production with Fe(II) concentra-
tion with 5 mmol/l DA and 5 mmol/l H2O2.
Fig. 3. Separation of a reaction mixture containing 5 mmol/l
DA, 2 mmol/l FeCl2, and 5 mmol/l H2O2 (detection at 265
nm).
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the platform than in any other quadrant (P6 0.002).
Although the amount of time spent in the former
platform quadrant by both groups was not signi¢-
cantly di¡erent, the saline-treated group exhibited no
speci¢c preference for the former platform quadrant
over the other three quadrants (Ps 0.05). Saline-
treated animals had a preference for both the former
platform quadrant and quadrant 3, as indicated by
no signi¢cant di¡erence in the percentage time spent
in these quadrants (Ps 0.05).
ROS formation in the neocortex, hippocampus,
and neostriatum from behaviorally tested animals
was not signi¢cantly a¡ected by nicotine, either over-
all or across time (Fig. 9). For all three brain areas,
however, ROS formation did increase over time
(P6 0.05). TBAR formation in the neocortex, hippo-
campus, and neostriatum was similarly una¡ected by
nicotine treatment in comparison to saline-treated
controls (Fig. 10A).
3.3. In vitro animal study
As shown in Fig. 10B, analysis of TBAR forma-
tion in neocortical homogenates revealed a 20-fold
increase in TBAR formation in saline homogenates
compared to Desferol-containing control homoge-
nates (P6 0.001). The 20-fold increase in TBAR for-
mation in saline homogenates was stimulated by
release of endogenous iron during tissue homogeni-
zation. This e¡ect of iron was dramatically decreased
by Desferol, an iron chelator. By contrast, nicotine
had no such e¡ect on the elevation in TBAR forma-
tion induced by endogenous iron since there was no
signi¢cant di¡erence in TBAR formation between
saline homogenates and the di¡erent nicotine homo-
genates (Ps 0.05 for all concentrations). There also
were no signi¢cant di¡erences between the various
nicotine homogenates in TBAR formation.
Fig. 8. Water maze acquisition (A) and memory retention (B)
for young adult rats being treated with nicotine or saline solu-
tion. In B, Q1^Q4 represent the pool’s four quadrants, with Q2
being the quadrant that formerly contained the escape platform.
Nicotine-treated animals, but not saline-treated animals, showed
a quadrant preference for Q2 in percent of swim time, indica-
tive of superior memory retention. The asterisk indicates a sig-
ni¢cant di¡erence (P6 0.05) from the other three quadrants.
Fig. 7. Formation of 6-OHDA in a mixture of 5 mmol/l DA,
1 mmol/l Fe(III), and 1 mmol/l H2O2 in the presence of
5 mmol/l nicotine (detection at 265 nm).
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4. Discussion
Given the inverse relationship between cigarette
smoking and both Parkinson’s and Alzheimer’s dis-
ease, it is possible that nicotine has certain bene¢cial/
protective e¡ects resulting in a preservation of motor
abilities and cognition, respectively. Indeed, nicotine
administration has been shown to decrease motor
disabilities in PD and improve cognitive performance
in AD patients [1^6,9^12]. The present study sought
to determine whether one possible mechanism of nic-
otine’s therapeutic/preventative actions could be
through antioxidant properties (i.e., via reduction
in oxidative stress reactions). With in vivo experi-
ments, we found no evidence that nicotine exerts
antioxidant capacities. However, in vitro experiments
appear to suggest a reduction of the Fenton activity
towards dopamine. Due to the experimental condi-
tions, quantitative results showing the dependence of
educt concentrations are not available and no de-
tailed kinetic or chemical mechanistic interpretation
is possible at the moment beside assuming that the
complex formation between nicotine and Fe(II) plays
a role, probably involving the oxidation of the nic-
otine.
A further possible explanation of the results might
be due to reaction 3, reported as a possible way to
prepare nicotine-pyrrolidinyloxide [21,22].
3
Fig. 10. (A) In vivo TBAR formation in neocortex, hippocam-
pus, and neostriatum from nicotine-treated and saline-treated
adult rats. (B) E¡ects of various nicotine concentrations on
neocortical TBAR formation in vitro. In both in vivo and in vi-
tro determinations, nicotine did not a¡ect TBAR formation.
Fig. 9. Time course of ROS formation in neocortex (A), neo-
striatum (B), and hippocampus (C) from nicotine-treated and
saline-treated adult rats. Nicotine had no e¡ect on ROS forma-
tion in any of the tissues analyzed.
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Attempts were made to follow this reaction by UV
absorption spectroscopy. An absorption maximum
of nicotine is found at 258 nm; its retention times
under the given HPLC conditions are larger than 20
min, excluding interference with the HPLC results
given above. The found kinetics indicate that this
reaction is much too slow to have any physiological
signi¢cance.
However, the results from the present study need
considerable further work (which indeed is currently
going on in our laboratory), to elucidate the exact
nature of the e¡ect of nicotine on the reaction be-
tween dopamine and Fenton’s reagent. It is entirely
possible that, if nicotine really does inhibit Parkin-
sonism, the mechanism involved could be totally dif-
ferent, i.e. not by preventing Fe(II) from producing
neurotoxic 6-OHDA. Along this line, nicotine has
recently been shown to increase the concentration
of dopamine in the brain [34]. In view of the inverse
relationship between cigarette smoking and PD [1^4],
it is also possible that other active substances in cig-
arette smoke (i.e., CO and CN3) are inhibitory to
the Fenton reaction. Since both CO and CN3 form
strong, low spin complexes with Fe(II), their Fenton
activity is presently being investigated in our labora-
tories.
Nicotine has a well-established cognition-enhanc-
ing e¡ect in both normal humans and those with AD
[9,12,35]. Numerous animal studies, including our
own studies in rats [13,14], have likewise indicated
a bene¢cial e¡ect of nicotine treatment on learning/
memory processes [35]. Because we have also shown
that treatment with antioxidants (both synthetic and
naturally occurring) can enhance cognitive perform-
ance in aged rats [28,36], it was reasonable to postu-
late that nicotine may be exerting some of its cogni-
tion-enhancing e¡ects through antioxidant
mechanisms. However, despite the ability of nicotine
in the present study to improve memory retention in
adult rats, there was no reduction in either ROS
formation or TBAR formation in brains from these
same behaviorally tested animals. Thus, nicotine did
not appear to a¡ect either reactive oxygen species
production or lipid peroxidation within cognitively
important brain areas (i.e., neocortex, hippocampus,
and neostriatum) in animals showing enhanced cog-
nition. Similarly, our follow-up in vitro experiment
involving neocortical homogenates indicated no sup-
pression of TBAR formation with various concentra-
tions of nicotine included in the incubation mixture.
No evidence for nicotine exerting anti-oxidant prop-
erties in brain tissue was, therefore, found. In earlier
studies involving white blood cells, evidence was pro-
vided for an antioxidant action of nicotine [37,38].
Results from these two studies and the present one
suggest that antioxidant actions of nicotine could be
tissue-speci¢c (i.e., present in blood cells, but not in
brain tissue). Alternatively, nicotine may have had
antioxidant actions in the brains of animals in our
study, with these e¡ects being manifested in oxidative
markers not measured (i.e., protein oxidation, DNA
oxidation, hydroxyl radical formation, etc.).
Finally, it is important to note that the bene¢cial/
preventative e¡ects of nicotine on motor and cogni-
tive skills could involve a variety of non-antioxidant
mechanisms acting separately or in concert with one
another. First, nicotine’s e¡ects may involve activa-
tion of postsynaptic or presynaptic nicotinic recep-
tors on neurons, with the latter resulting in release of
acetylcholine and non-cholinergic neurotransmitters
[39,40]. Second, nicotine has the ability to increase
glucose uptake in the brain [41,42]. In this context, it
is noteworthy that glucose administration to AD pa-
tients improves their cognitive performance [43].
Third, nicotine administration increases regional cer-
ebral blood £ow [44,45], thus having potentially ben-
e¢cial e¡ects on neuronal function/survivability.
In summary, our chromatographic experiments
suggest that nicotine might provide some of its ther-
apeutic actions in PD and AD through antioxidant
mechanisms. Our animal experiments, however, sug-
gest that non-antioxidant mechanisms are primarily
responsible for nicotine’s multiplicity of motor/cog-
nitive actions.
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